Kontafarma China Holdings Ltd (1312) AI Stock Analysis

• Market Cap: HK$156.20M
• Dividend Yield: N/A
• Average Volume (3M): 9.95M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: 6.55%
• EPS Growth: -475.22%
• Country: HK
• Employees: 714
• Sector: Healthcare
• Sector Strength: 45
• Industry: Construction Materials
• EPS (TTM): -0.05
• Shares Outstanding: 5,588,572,000
• 10 Day Avg. Volume: 1,701,000
• 30 Day Avg. Volume: 9,954,100
• PEG Ratio: -0.01
• Price to Book (P/B): 0.15
• Price to Sales (P/S): 0.16
• P/FCF Ratio: 4.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$0.03 ▼(-6.67% Downside)

Kontafarma China Holdings Ltd's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability issues. Technical analysis suggests neutral to slightly bearish momentum, while poor valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves these areas unaddressed.

Positive Factors

Market Demand

The increasing demand for healthcare products in China provides a strong market opportunity for Kontafarma, supporting potential long-term revenue growth.

Business Model Diversification

A diversified revenue model with multiple streams, including prescription and OTC products, helps mitigate risks and stabilize income, enhancing business resilience.

Strategic Partnerships

Strategic partnerships for R&D can drive innovation and product development, potentially leading to new revenue streams and competitive advantages.

Negative Factors

Profitability Issues

Persistent profitability challenges and declining revenues indicate difficulties in maintaining market share and pricing power, affecting long-term sustainability.

Weak Cash Flow

Inconsistent cash flow generation limits the company's ability to fund operations and growth internally, posing risks to financial stability and expansion plans.

Declining Equity

Continuous losses leading to declining equity weaken the financial position, reducing the company's ability to leverage financing for growth and operations.

Kontafarma China Holdings Ltd Business Overview & Revenue Model

Company Description

Kontafarma China Holdings Ltd. engages in the manufacture and sale of cement. It operates through the following segments: Pharmaceutical and Fitness Business. The Pharmaceutical Business segment involves in manufacture and sales of prescription drugs and laboratory related products. The Fitness Business segment includes the operation of fitness centers and provide consultation services for fitness and health activities and operate the franchise business for royalty fee income. The company was founded on March 21, 2011 and is headquartered in Hong Kong.

How the Company Makes Money

Kontafarma generates revenue through multiple streams, primarily from the sale of pharmaceutical products, which includes both prescription and over-the-counter medications. The company capitalizes on its extensive distribution network to reach hospitals, clinics, and retail pharmacies across China. Additionally, Kontafarma may receive income from collaborations or partnerships with healthcare institutions and other pharmaceutical companies for research and development initiatives. The growing demand for healthcare products in China, driven by an aging population and increasing health awareness, also contributes significantly to its revenue growth.

Kontafarma China Holdings Ltd Financial Statement Overview

Summary

Kontafarma China Holdings Ltd is facing significant financial challenges. The income statement reflects ongoing profitability issues, exacerbated by declining revenues. The balance sheet shows a weakening financial position, while cash flows are inconsistent, highlighting operational and financial risks. Strategic pivots or efficiency improvements are needed to stabilize and grow the business.

Income Statement

Kontafarma China Holdings Ltd shows declining revenue and profitability. The net profit margin is negative due to consistent net losses, and EBIT margins remain poor. Revenue growth has been negative or stagnant, reflecting challenges in maintaining market share or pricing power.

Balance Sheet

The company's balance sheet indicates moderate leverage with a debt-to-equity ratio that has been manageable, but declining equity due to continuous losses is a concern. The equity ratio suggests moderate reliance on equity financing, but the decreasing total assets are troubling.

Cash Flow

Cash flow performance is weak with erratic operating cash flow and negative free cash flow in recent years. The inability to consistently generate free cash flow raises concerns about the company's capacity to fund operations and growth internally.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	891.73M	897.52M	809.11M	894.06M	803.27M	1.01B
Gross Profit	493.63M	516.16M	471.29M	506.22M	396.18M	555.75M
EBITDA	-79.14M	-49.93M	78.50M	26.93M	112.18M	156.31M
Net Income	-362.77M	-75.54M	-28.84M	-41.55M	-15.05M	-267.16M
Balance Sheet
Total Assets	1.15B	1.59B	1.73B	2.12B	2.56B	2.54B
Cash, Cash Equivalents and Short-Term Investments	78.33M	90.58M	87.66M	142.59M	183.96M	194.79M
Total Debt	235.86M	297.19M	333.82M	590.72M	728.95M	782.61M
Total Liabilities	532.12M	625.90M	665.39M	964.16M	1.22B	1.19B
Stockholders Equity	684.99M	978.70M	1.06B	1.10B	1.19B	1.21B
Cash Flow
Free Cash Flow	32.13M	33.41M	12.92M	-53.84M	-49.31M	51.02M
Operating Cash Flow	49.63M	47.05M	37.12M	-2.17M	75.07M	206.93M
Investing Cash Flow	6.74M	-6.01M	144.14M	121.53M	23.24M	-206.12M
Financing Cash Flow	-35.78M	-42.52M	-198.81M	-137.33M	-99.80M	19.10M

Kontafarma China Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.74 is Neutral, neither overbought nor oversold. The STOCH value of 57.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1312.

Kontafarma China Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0858	54 Neutral	HK$229.50M	0.97	-32.04%	―	-11.89%	-290.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$580.83M	―	-40.38%	―	-43.46%	-96.48%
8622	48 Neutral	HK$230.22M	―	-8.71%	―	2.54%	33.33%
1312	46 Neutral	HK$156.20M	-0.43	-41.48%	―	6.55%	-475.22%
1498	41 Neutral	HK$213.98M	-4.10	-33.22%	―	-17.32%	55.74%
1011	41 Neutral	HK$485.46M	-2.86	―	―	―	―

Kontafarma China Holdings Ltd Corporate Events

Kontafarma Announces Executive Resignation

Kontafarma China Holdings Limited announced the resignation of Ms. Qiao Linna from her roles as an executive director and vice president, effective November 14, 2025. Ms. Qiao’s departure also results in her cessation as a member of the company’s executive and share dealing committees. The board expressed gratitude for her contributions and confirmed there are no disagreements or issues requiring shareholder attention.

Kontafarma China Holdings Ltd Announces Board Restructuring

Kontafarma China Holdings Ltd has announced a restructuring of its board of directors, effective November 14, 2025. The company has appointed Wang Feifei as Chairman and President, with Guo Zixiu as Financial Controller, and Liu Jiankun as an Executive Director. The board also includes a Non-Executive Director and three Independent Non-Executive Directors. This restructuring is likely to impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder confidence.

Kontafarma China Approves Major R&D Construction Contract

Kontafarma China Holdings Ltd announced that its adjourned extraordinary general meeting successfully passed all proposed resolutions, including the approval of a significant construction contract for a research and development complex in Beijing. This contract, valued at over RMB33 million, is expected to enhance the company’s R&D capabilities, potentially strengthening its market position and benefiting stakeholders.

Kontafarma China Holdings Ltd Reschedules Extraordinary General Meeting

Kontafarma China Holdings Ltd has announced the adjournment of its Extraordinary General Meeting (EGM) initially scheduled for October 20, 2025, to November 7, 2025, due to the need for additional preparation time. The venue remains unchanged, and the period for determining shareholder entitlements to attend and vote also remains the same. Shareholders who have already submitted proxy forms do not need to resubmit them, as they remain valid for the adjourned meeting.

Kontafarma Faces Potential Winding Up of Taiwanese Associate

Kontafarma China Holdings Ltd announced the potential winding up of its associate, True Concept Ltd, due to severe operational challenges and financial constraints in the Taiwanese fitness industry. Despite efforts to improve conditions, True Concept’s business has deteriorated, leading to the closure of its fitness centers and potential legal proceedings for liquidation. The company has recognized significant impairment losses, and True Concept’s total debts exceed HK$771.1 million, affecting various stakeholders including employees and creditors.

Kontafarma China Holdings Plans New R&D Complex in Beijing

Kontafarma China Holdings Ltd has announced an extraordinary general meeting to approve a construction contract for a new R&D complex in Beijing. This development signifies the company’s commitment to expanding its research capabilities, potentially enhancing its market position and offering growth opportunities for stakeholders.

Kontafarma China Holdings Delays Circular Dispatch for Beijing Project

Kontafarma China Holdings Ltd announced a delay in the dispatch of a circular related to a discloseable and connected transaction concerning the Beijing Construction Contract for the Beijing R&D Complex Project. The delay is due to the need for additional time to finalize certain information, and the company is seeking a waiver from the Stock Exchange to extend the dispatch date to on or before 30 September 2025.

Kontafarma China Holdings Reports Significant Interim Losses

Kontafarma China Holdings Ltd reported its unaudited interim results for the six months ending June 30, 2025, showing a significant financial downturn compared to the previous year. The company experienced a substantial loss of HK$321.4 million, primarily due to increased impairment losses and other financial setbacks, impacting its profitability and market position.